#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 10

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Colorectal cancer metastatic+1

Not recruiting

Registered drugNo placebo

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cetuximab

Contact Research Centre

Triple negative breast cancer+1

Not recruiting

Investigational

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate

Contact Research Centre

Malignant melanoma

Not recruiting

Registered drugNo placebo

Study on Ceralasertib and Durvalumab for Patients with Advanced Melanoma Resistant to PD-(L)1 Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ceralasertib

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carfilzomib

Contact Research Centre

Neoplasm malignant

Not recruiting

Registered drugNo placebo

Study of Lurbinectedin and Irinotecan for Patients with Advanced Solid Tumors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Irinotecan

Contact Research Centre

Giant cell tumour of tendon sheath

Not recruiting

Investigational

Study of emactuzumab compared to placebo in patients with tenosynovial giant cell tumor

Investigational

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Emactuzumab

Contact Research Centre

Cholangiocarcinoma

Not recruiting

Registered drugNo placebo

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Registered drugNo placebo

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Gad20-209-Fsp-A1

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Liposarcoma

Not recruiting

Registered drugNo placebo

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing Panitumumab and Regorafenib Sequence for Patients with Metastatic Colorectal Cancer Resistant to Previous Treatments

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Panitumumab

Contact Research Centre

Metastatic renal cell carcinoma

Not recruiting

Registered drugNo placebo

Study on Pembrolizumab for Patients with Resectable Metastases from Kidney Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.